Quality of life of patients with hematological malignancies and factors affecting health state utility values

Osaki, Keiichi; Morishita, Shinichiro; Takami, Suzuho; Sakai, Yuki; Kamimura, Akiho; Shindo, Atsushi; Kawata, Eri

doi:10.1007/s00520-022-06958-y

Cited by 5 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deficits in neuromuscular strength are also a common facet of sensorimotor impairment (Osaki, Morishita et al 2022). Both fore– and hind-limb grip strength was reduced in doxorubicin-treated mice, compared to control mice ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Systemic and targeted activation of Nrf2 reverses doxorubicin-induced cognitive impairments and sensorimotor deficits in mice

Singh,

Ruiz,

Ur Rasheed

et al. 2024

Preprint

View full text Add to dashboard Cite

While cancer survivorship has increased due to advances in treatments, chemotherapy often carries long-lived neurotoxic side effects which reduce quality of life. Commonly affected domains include memory, executive function, attention, processing speed and sensorimotor function, colloquially known as chemotherapy-induced cognitive impairment (CICI) or “chemobrain”. Oxidative stress and neuroimmune signaling in the brain have been mechanistically linked to the deleterious effects of chemotherapy on cognition and sensorimotor function. With this in mind, we tested if activation of the master regulator of antioxidant response nuclear factor E2-related factor 2 (Nrf2) alleviates cognitive and sensorimotor impairments induced by doxorubicin. The FDA-approved systemic Nrf2 activator, diroximel fumarate (DRF) was used, along with our recently developed prodrug1cwhich has the advantage of specifically releasing monomethyl fumarate at sites of oxidative stress. DRF and1cboth reversed doxorubicin-induced deficits in executive function, spatial and working memory, as well as decrements in fine motor coordination and grip strength, across both male and female mice. Both treatments reversed doxorubicin-induced loss of synaptic proteins and microglia phenotypic transition in the hippocampus. Doxorubicin-induced myelin damage in the corpus callosum was reversed by both Nrf2 activators. These results demonstrate the therapeutic potential of Nrf2 activators to reverse doxorubicin-induced cognitive impairments, motor incoordination, and associated structural and phenotypic changes in the brain. The localized release of monomethyl fumarate by1chas the potential to diminish unwanted effects of fumarates while retaining efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Systemic and targeted activation of Nrf2 reverses doxorubicin-induced cognitive impairments and sensorimotor deficits in mice

Singh,

Ruiz,

Ur Rasheed

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Herdman et al proposed a more detailed version of the questionnaire, the EQ-5D-5L, in which five instead of three scores are given to each evaluated parameter [ 27 ]. However, whether the proposed method is superior remains to be tested [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…It suggests that Hb might be important, but is not the only factor affecting QoL. As other publications have suggested, additional variables might affect QoL, such as an older age, female sex, comorbidities, a high body mass index, and physical function and performance status, as well as RBC transfusion need, leukocytosis, neutrophilia, lymphocytosis, monocytosis, thrombocytosis, a high neutrophil to lymphocyte ratio, and high serum ferritin level [ 12 , 29 , 34 , 42 , 43 , 44 , 45 ]. This will have to be taken into consideration in the future when designing therapies intended to improve QoL.…”

Section: Discussionmentioning

confidence: 99%

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level

Haring,

Goldschmidt,

Taha

et al. 2023

JCM

View full text Add to dashboard Cite

Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.

show abstract

“…Scores of 12 points or higher indicate normal nutritional status, and scores of 11 points or below indicate possible malnutrition [23]. The MNA-SF has been widely used to assess the nutritional status of cancer patients in previous studies [24,25]. The inter-observer reliability coe cient for MNA-SF was 0.97.…”

Section: Mini Nutritional Assessment (Mna) Short Formmentioning

confidence: 99%

Factors associated with functional ability in patients with esophageal cancer undergoing chemoradiotherapy: a prospective longitudinal study Running head: Patient functional ability in unresectable EC

Lee,

Huang,

Tseng

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose During and after treatment, esophageal cancer (EC) patients experience changes in body mass index (BMI), performance status, nutrition status, symptom distress, and physical fitness. This study aims to evaluate temporal changes and their associated factors in BMI, performance status, nutrition status, symptom distress, physical fitness, and functional ability in EC patients during and after treatment. Methods This prospective longitudinal study recruited EC patients from a medical center in Northern Taiwan. The 112 EC patients were assessed before treatment (T0), 1 month after starting treatment (T1), 3 months after starting treatment (end of treatment) (T2), and 6 months after starting treatment (T3). Generalized estimating equation analysis was used to determine the factors associated with changes in functional ability over time. Results Patient nutrition status was lowest before treatment and then increased by 6 months after treatment. Symptom distress slightly decreased from before treatment to 3 months after treatment, rising at 6 months after treatment but not reaching baseline (T0). Functional ability increased from before treatment to 1 month after treatment and then declined at 3 months after starting treatment, increasing at 6 months to below baseline (T0). Patients who had a BMI less than 25 kg/m2, engaged less in physical activity, and were less physically fit were more likely to have worse functional ability. Conclusion BMI, level of physical activity, and the degree of physical fitness were the important factors associated with functional ability in EC patients. Healthcare professionals should design patient-tailored prehabilitation programs in advance to strengthen physical fitness.

show abstract

Quality of life of patients with hematological malignancies and factors affecting health state utility values

Cited by 5 publications

References 42 publications

Systemic and targeted activation of Nrf2 reverses doxorubicin-induced cognitive impairments and sensorimotor deficits in mice

Systemic and targeted activation of Nrf2 reverses doxorubicin-induced cognitive impairments and sensorimotor deficits in mice

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level

Factors associated with functional ability in patients with esophageal cancer undergoing chemoradiotherapy: a prospective longitudinal study Running head: Patient functional ability in unresectable EC

Contact Info

Product

Resources

About